The Impact of Enteral Versus Oral Protein Feeding on Muscle Protein Synthesis in Healthy Young Males and Females
NCT ID: NCT03571425
Last Updated: 2018-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2018-06-04
2018-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral Placebo
Placebo drink
Oral Placebo
A placebo beverage will be consumed orally
Oral Protein
Protein drink, ingested orally
Oral Protein
A protein beverage will be consumed orally
Enteral Protein
Protein drink, administered via enteral tube
Enteral Protein
A protein beverage will be consumed via a naso-gastric feeding tube
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral Placebo
A placebo beverage will be consumed orally
Oral Protein
A protein beverage will be consumed orally
Enteral Protein
A protein beverage will be consumed via a naso-gastric feeding tube
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index between 18.5 and 30
Exclusion Criteria
* Any diagnosed cardiovascular disease
* Elevated blood pressure at the time of screening. (An average systolic blood pressure reading of ≥140 mmHg over two or more measurements and an average diastolic blood pressure of ≥90 mmHg over two or more measurements)
* Chronic use of any prescribed or over the counter pharmaceuticals (that may modulate muscle protein metabolism). This excludes oral contraceptives and contraceptive devices.
* A personal or family history of epilepsy, seizures or schizophrenia.
* Presence of an ulcer in the stomach or gut and/or strong history of indigestion
* Known pre-existing liver disease/condition
* Any known disorders in muscle metabolism
* Regular use of nutritional supplements
* Allergy to lidocaine
* Allergy to milk
* Current paracetamol use (i.e. use of paracetamol more than once a week)
* Pregnancy
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Exeter
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Marlou Dirks, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Exeter
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Exeter
Exeter, Devon, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
180509/B/03
Identifier Type: -
Identifier Source: org_study_id